Selenium Sulfide

Summary

Selenium Sulfide (CHEMBL1200680) is an approved small molecule (ATC D01AE13); indicated across 4 conditions including tinea infection and seborrheic dermatitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AE13
• Indications: 4 conditions
• Clinical trials: 2
• Chemistry: 143.1 Da · S2Se

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200680
Name	Selenium Sulfide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	24087
ATC	D01AE13
Molecular formula	S2Se
Molecular weight	143.1
InChIKey	JNMWHTHYDQTDQZ-UHFFFAOYSA-N

SMILES: S=[Se]=S

Also known as: Exsel, Lenium, Seledruff, Selenii disulfidum, Selenium disulfide, Selenium sulfide, Selenium sulfide (ses(sub 2)), micronized, Selenium sulphide (ses2), Selenium sulphide, Selsun, SELENIUM SULFIDE

Patent coverage: 1,786 distinct patent families (4,124 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tinea infection	4	MONDO:0005982	EFO:0007510
seborrheic dermatitis	4	MONDO:0006608	EFO:1000764

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07133334	Not specified	COMPLETED	Evaluation and Comparison of the Benefits of Routine vs Shampoo Alone During 4 Weeks Treatment and 12 Weeks Remanence
NCT07292467	Not specified	COMPLETED	Evaluation of the Benefits of Shampoo During 4 Weeks of Treatment and After 24 Weeks

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).